沙砾生物
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting 2025-12-06 22:45
Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801 2025-11-04 21:15
Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting 2025-05-29 20:30
Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting 2025-05-12 20:30
GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer 2025-01-03 15:30
GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2 2024-05-31 21:16
Grit Biotechnology Announces Closing of $60 Million Series B Financing 2023-09-08 17:00
1